[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fP_su09zqdFkxZ97_nLnURcId7FVIfEjwjRoJMXyARME":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":82,"rows":89},"Shandong Suncadia Medicine Co., Ltd.",[4],78,false,39,11,18654,65,0,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Type 2 Diabetes",7,{"name":18,"count":19},"Breast Cancer",6,{"name":21,"count":22},"Type 2 Diabetes Mellitus",4,{"name":24,"count":22},"Chronic Kidney Disease",{"name":26,"count":22},"Obstructive Hypertrophic Cardiomyopathy",{"name":28,"count":29},"Hyperlipidemia",3,{"name":31,"count":32},"Pain",2,{"name":34,"count":32},"Advanced Malignant Tumour",[36,41,46,51,55,60,64,69,73,78],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06516068","A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy","2024-11-18","HRS-1893",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06621316","A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects","2025-05-30","HRS-7535",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05628870","A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer","2025-06","HRS-1358",{"nctId":52,"briefTitle":53,"date":54,"intervention":40},"NCT06816251","A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy","2025-08",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07185594","A Phase Ⅱ\u002FⅢ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery","2025-12","HRS-2129",{"nctId":61,"briefTitle":62,"date":63,"intervention":45},"NCT06589765","A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin","2026-02-18",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07320521","A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.","2026-03","[14C]HRS-8080",{"nctId":70,"briefTitle":71,"date":72,"intervention":45},"NCT06904105","A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity","2026-05",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06167694","Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer","2026-06","HRS-8080; Dalpiciclib Isethionate",{"nctId":79,"briefTitle":80,"date":76,"intervention":81},"NCT07557407","A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male Subjects","[14C]HRS-1780",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,273,362,442,522,548,596,643,665,687,709,731,753,775,793,819,837,855,873,891,909,927,945,1004,1028,1050,1077,1103,1138,1173,1191,1209,1227,1245,1263,1281,1299,1317,1335,1353,1371,1389,1407,1433,1451,1469,1490,1514,1532,1550,1580,1598,1616,1634,1652,1670,1688,1706,1728,1747,1770,1795,1813,1837,1855,1873,1907,1932,1957,1979,1997,2015,2033,2051,2075,2093,2117,2135,2161,2179,2197,2221,2246,2264,2293,2311,2329,2347,2365,2383,2405,2429,2454,2476,2502,2520,2538,2556],{"intervention":45,"totalTrials":91,"cells":92},16,{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":166,"PHASE3":230,"PHASE4":269,"NA":271},{"trials":94,"activeCount":12},[],{"trials":96,"activeCount":12},[97,109,121,129,139,151],{"nctId":98,"briefTitle":99,"status":100,"phases":101,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":106},"NCT06495931","Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human","COMPLETED",[84],"2024-08-13","2024-07-15",24,[21],[107,108,45],"HRS-1780","HR20033",{"nctId":110,"briefTitle":111,"status":100,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT06727838","Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Human",[84],"2025-01-25","2024-12-31",18,[117],"Diabetes",[45,119,120],"Metformin Hydrochloride Extended-release","Metformin Hydrochloride",{"nctId":122,"briefTitle":123,"status":100,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":91,"conditions":127,"interventions":128},"NCT06132204","Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects",[84],"2024-03-13","2023-12-21",[15],[45],{"nctId":130,"briefTitle":131,"status":100,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":104,"conditions":135,"interventions":136},"NCT06422039","Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects",[84],"2024-08-06","2024-05-23",[21],[137,138],"HRS-7535(D)","HRS-7535(C)",{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},"NCT05347758","A Phase I Single- and Multiple- Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy Subjects","UNKNOWN",[84],"2022-09-18","2023-03-15","2022-05-01",106,[149],"Healthy Subjects",[45],{"nctId":152,"briefTitle":153,"status":100,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":161},"NCT07269756","A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects",[84],"2026-03-08","2025-12-08",40,[159,160],"Obesity","Overweight",[45,162,163,164,165],"Paracetamol","Digoxin","Rosuvastatin Calcium","Omeprazole Enteric-coated",{"trials":167,"activeCount":32,"soonestReadout":44},[168,177,187,199,208,219],{"nctId":42,"briefTitle":43,"status":169,"phases":170,"primaryCompletion":44,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":176},"ACTIVE_NOT_RECRUITING",[84,85],"2025-06-30","2024-10-30",74,[175],"Overweight or Obesity",[45],{"nctId":178,"briefTitle":179,"status":100,"phases":180,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":186},"NCT06393348","Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.",[85],"2024-11-15","2025-03-13","2024-05-17",155,[15],[45],{"nctId":188,"briefTitle":189,"status":190,"phases":191,"primaryCompletion":192,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT06820099","Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction\u002FPreserved Ejection Fraction Heart Failure and Obesity","RECRUITING",[85],"2026-12","2025-04-10",225,[196],"Adults With Heart Failure, Mild Decrease in Ejection Fraction\u002FPreserved Ejection Fraction, and Obesity",[45,198],"HRS-7535 tablet placebo",{"nctId":200,"briefTitle":201,"status":142,"phases":202,"primaryCompletion":126,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NCT05759897","A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus",[85],"2024-01-04","2023-02-28",180,[15],[45],{"nctId":209,"briefTitle":210,"status":100,"phases":211,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":218},"NCT06671821","Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects",[85],"2025-08-15","2025-09-28","2024-11-20",81,[217],"Chronic Weight Management",[45],{"nctId":220,"briefTitle":221,"status":100,"phases":222,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT06415214","Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes",[85],"2025-07-15","2025-07-25","2024-06-21",281,[228],"Diabetic Kidney Disease, Type 2 Diabetes",[45],{"trials":231,"activeCount":29,"soonestReadout":63},[232,239,250,261],{"nctId":70,"briefTitle":71,"status":169,"phases":233,"primaryCompletion":72,"completion":72,"start":234,"enrollment":235,"conditions":236,"interventions":237},[86],"2025-04-09",556,[160,159],[45,238],"HRS-7535 Placebo",{"nctId":240,"briefTitle":241,"status":100,"phases":242,"primaryCompletion":243,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":248},"NCT06672172","A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise",[86],"2025-11-13","2026-04-17","2024-09-25",284,[15],[45,45,45,249],"HRS-7535 placebo",{"nctId":251,"briefTitle":252,"status":253,"phases":254,"primaryCompletion":255,"completion":256,"start":72,"enrollment":257,"conditions":258,"interventions":260},"NCT07528027","Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity","NOT_YET_RECRUITING",[86],"2027-12","2028-01",648,[259],"Hypertension With Overweight or Obesity",[45],{"nctId":61,"briefTitle":62,"status":190,"phases":262,"primaryCompletion":63,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":267},[86],"2026-07-18","2024-09-27",800,[15],[45,268],"dapagliflozin",{"trials":270,"activeCount":12},[],{"trials":272,"activeCount":12},[],{"intervention":40,"totalTrials":274,"cells":275},8,{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":308,"PHASE3":344,"PHASE4":358,"NA":360},{"trials":277,"activeCount":12},[],{"trials":279,"activeCount":12},[280,289,299],{"nctId":281,"briefTitle":282,"status":100,"phases":283,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":288},"NCT05879523","A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy",[84],"2024-03-21","2023-06-05",76,[26],[40],{"nctId":290,"briefTitle":291,"status":100,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":297},"NCT06354556","Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects",[84],"2024-05-20","2024-04-26",14,[26],[40,298],"Verapamil",{"nctId":300,"briefTitle":301,"status":100,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":104,"conditions":305,"interventions":307},"NCT06775834","Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function",[84],"2025-07-23","2025-02-11",[306],"Hypertrophic Cardiomyopathy",[40],{"trials":309,"activeCount":22,"soonestReadout":39},[310,316,324,332],{"nctId":37,"briefTitle":38,"status":169,"phases":311,"primaryCompletion":39,"completion":54,"start":312,"enrollment":313,"conditions":314,"interventions":315},[85],"2024-08-11",42,[26],[40],{"nctId":52,"briefTitle":53,"status":190,"phases":317,"primaryCompletion":54,"completion":54,"start":318,"enrollment":319,"conditions":320,"interventions":322},[85],"2025-02-25",84,[321],"Non-obstructive Hypertrophic Cardiomyopathy",[40,323],"HRS-1893 placebo",{"nctId":325,"briefTitle":326,"status":190,"phases":327,"primaryCompletion":255,"completion":255,"start":328,"enrollment":329,"conditions":330,"interventions":331},"NCT07021963","A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy",[85],"2025-07-04",300,[306],[40],{"nctId":333,"briefTitle":334,"status":190,"phases":335,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":342},"NCT07269717","A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction",[85],"2027-03","2027-05","2026-03-30",48,[341],"Heart Failure With Preserved Ejection Fraction",[40,343],"HRS-1893 Tablet Placebo",{"trials":345,"activeCount":357,"soonestReadout":350},[346],{"nctId":347,"briefTitle":348,"status":190,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":355},"NCT07021976","A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy",[86],"2026-09","2026-11","2025-08-11",216,[26],[40,356],"HRS-1893 Placebo",1,{"trials":359,"activeCount":12},[],{"trials":361,"activeCount":12},[],{"intervention":363,"totalTrials":19,"cells":364},"HRS-8080",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":386,"PHASE3":413,"PHASE4":438,"NA":440},{"trials":366,"activeCount":12},[],{"trials":368,"activeCount":12},[369,378],{"nctId":370,"briefTitle":371,"status":100,"phases":372,"primaryCompletion":373,"completion":373,"start":374,"enrollment":91,"conditions":375,"interventions":376},"NCT07229560","A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants",[84],"2025-12-31","2025-11-26",[18],[363,377],"Itraconazole",{"nctId":379,"briefTitle":380,"status":100,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":104,"conditions":384,"interventions":385},"NCT06619873","A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects",[84],"2024-11-13","2024-10-10",[18],[363],{"trials":387,"activeCount":32,"soonestReadout":392},[388,401],{"nctId":389,"briefTitle":390,"status":190,"phases":391,"primaryCompletion":392,"completion":393,"start":394,"enrollment":329,"conditions":395,"interventions":397},"NCT06679036","A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients",[84,85],"2026-10-30","2026-12-31","2025-01-21",[396],"Advanced Unresectable or Metastatic Breast Cancer",[398,399,363,400,50],"HRS-2189","Fluvustat","HRS-6209",{"nctId":402,"briefTitle":403,"status":190,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":205,"conditions":407,"interventions":409},"NCT07389733","A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer",[84,85],"2028-12","2026-03-27",[408],"Advanced Unresectable or Metastatic Breast Cancer of Adults",[410,400,363,411,412],"HRS-6208","Fulvestrant","Letrozole",{"trials":414,"activeCount":32,"soonestReadout":192},[415,428],{"nctId":416,"briefTitle":417,"status":190,"phases":418,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT07349069","A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer",[86],"2030-12","2034-01","2026-03-04",5500,[18],[363,412,425,426,427],"Tamoxifen Citrate","Anastrozole","Exemestane",{"nctId":429,"briefTitle":430,"status":190,"phases":431,"primaryCompletion":192,"completion":255,"start":303,"enrollment":432,"conditions":433,"interventions":436},"NCT07024173","A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer",[86],240,[434,435],"Locally Advanced Breast Cancer","Metastatic Breast Cancer",[363,411,427,437,426,412],"Everolimus",{"trials":439,"activeCount":12},[],{"trials":441,"activeCount":12},[],{"intervention":59,"totalTrials":19,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":493,"PHASE3":507,"PHASE4":518,"NA":520},{"trials":445,"activeCount":12},[],{"trials":447,"activeCount":32,"soonestReadout":483},[448,458,468,479],{"nctId":449,"briefTitle":450,"status":100,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":456},"NCT06619392","A Single Dose Escalation Trial of HRS-2129 in Healthy Subjects",[84],"2025-01-20","2024-10-17",44,[31],[59,457],"HRS-2129 Placebo",{"nctId":459,"briefTitle":460,"status":100,"phases":461,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":466},"NCT06742840","A Multiple Ascending Dose Trial of HRS-2129 in Healthy Subjects",[84],"2025-07-02","2024-12-30",23,[31],[59,467],"HRS-2129 placebo",{"nctId":469,"briefTitle":470,"status":190,"phases":471,"primaryCompletion":350,"completion":351,"start":472,"enrollment":473,"conditions":474,"interventions":476},"NCT07377721","A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain",[84],"2026-03-24",168,[475],"Diabetic Peripheral Neuropathic Pain",[59,457,477,478],"Pregabalin","Pregabalin Capsules Placebo",{"nctId":480,"briefTitle":481,"status":190,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":489},"NCT07351968","A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis",[84],"2026-08","2026-03-10",200,[487,488],"Moderate Pain in Knee Osteoarthritis","Severe Pain in Knee Osteoarthritis",[59,490,491,492],"Celecoxib","Celecoxib Capsule Placebo","HRS-2129 Tablet Placebo",{"trials":494,"activeCount":12},[495],{"nctId":496,"briefTitle":497,"status":100,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":505},"NCT06780267","Clinical Study of HRS-2129 for Postoperative Analgesia in Orthopaedics",[84,85],"2026-03-19","2026-04-03","2025-03-11",199,[504],"Postoperative Pain in Orthopaedics",[59,467,506],"Tramadol Hydrochloride SR",{"trials":508,"activeCount":357,"soonestReadout":58},[509],{"nctId":56,"briefTitle":57,"status":190,"phases":510,"primaryCompletion":58,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":516},[85,86],"2026-01","2025-10-24",360,[515],"Postoperative Analgesia",[59,517,506],"Blank Preparation.",{"trials":519,"activeCount":12},[],{"trials":521,"activeCount":12},[],{"intervention":412,"totalTrials":29,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":534,"PHASE4":544,"NA":546},{"trials":525,"activeCount":12},[],{"trials":527,"activeCount":12},[],{"trials":529,"activeCount":357,"soonestReadout":405},[530],{"nctId":402,"briefTitle":403,"status":190,"phases":531,"primaryCompletion":405,"completion":405,"start":406,"enrollment":205,"conditions":532,"interventions":533},[84,85],[408],[410,400,363,411,412],{"trials":535,"activeCount":32,"soonestReadout":192},[536,540],{"nctId":416,"briefTitle":417,"status":190,"phases":537,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":538,"interventions":539},[86],[18],[363,412,425,426,427],{"nctId":429,"briefTitle":430,"status":190,"phases":541,"primaryCompletion":192,"completion":255,"start":303,"enrollment":432,"conditions":542,"interventions":543},[86],[434,435],[363,411,427,437,426,412],{"trials":545,"activeCount":12},[],{"trials":547,"activeCount":12},[],{"intervention":549,"totalTrials":29,"cells":550},"HRS-7058",{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":577,"PHASE4":592,"NA":594},{"trials":552,"activeCount":12},[],{"trials":554,"activeCount":12},[],{"trials":556,"activeCount":32,"soonestReadout":561},[557,568],{"nctId":558,"briefTitle":559,"status":190,"phases":560,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT07032077","A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors",[85],"2027-06","2027-07","2025-07-09",100,[566],"Solid Tumors",[549],{"nctId":569,"briefTitle":570,"status":190,"phases":571,"primaryCompletion":405,"completion":405,"start":572,"enrollment":573,"conditions":574,"interventions":576},"NCT07589569","An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer",[85],"2026-05-21",92,[575],"Pancreatic Cancer",[549],{"trials":578,"activeCount":357,"soonestReadout":583},[579],{"nctId":580,"briefTitle":581,"status":253,"phases":582,"primaryCompletion":583,"completion":584,"start":76,"enrollment":585,"conditions":586,"interventions":588},"NCT07601048","A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment",[86],"2028-05","2029-05",450,[587],"KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment",[549,589,590,591],"Fulzerasib","Garsorasib","Glecirasib Citrate",{"trials":593,"activeCount":12},[],{"trials":595,"activeCount":12},[],{"intervention":107,"totalTrials":22,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":616,"PHASE3":627,"PHASE4":639,"NA":641},{"trials":599,"activeCount":12},[],{"trials":601,"activeCount":12},[602,606],{"nctId":98,"briefTitle":99,"status":100,"phases":603,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":604,"interventions":605},[84],[21],[107,108,45],{"nctId":607,"briefTitle":608,"status":142,"phases":609,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":615},"NCT06039254","Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function",[84],"2023-11-30","2023-12-08","2023-09",27,[24],[107],{"trials":617,"activeCount":357,"soonestReadout":351},[618],{"nctId":619,"briefTitle":620,"status":190,"phases":621,"primaryCompletion":351,"completion":351,"start":622,"enrollment":623,"conditions":624,"interventions":626},"NCT07470983","A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism",[85],"2026-04-23",60,[625],"Primary Aldosteronism",[107],{"trials":628,"activeCount":357,"soonestReadout":633},[629],{"nctId":630,"briefTitle":631,"status":190,"phases":632,"primaryCompletion":633,"completion":634,"start":635,"enrollment":636,"conditions":637,"interventions":638},"NCT07419828","A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease",[86],"2030-04","2030-05","2026-03-13",1978,[24],[107],{"trials":640,"activeCount":12},[],{"trials":642,"activeCount":12},[],{"intervention":426,"totalTrials":32,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":661,"NA":663},{"trials":646,"activeCount":12},[],{"trials":648,"activeCount":12},[],{"trials":650,"activeCount":12},[],{"trials":652,"activeCount":32,"soonestReadout":192},[653,657],{"nctId":416,"briefTitle":417,"status":190,"phases":654,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":655,"interventions":656},[86],[18],[363,412,425,426,427],{"nctId":429,"briefTitle":430,"status":190,"phases":658,"primaryCompletion":192,"completion":255,"start":303,"enrollment":432,"conditions":659,"interventions":660},[86],[434,435],[363,411,427,437,426,412],{"trials":662,"activeCount":12},[],{"trials":664,"activeCount":12},[],{"intervention":427,"totalTrials":32,"cells":666},{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":673,"PHASE4":683,"NA":685},{"trials":668,"activeCount":12},[],{"trials":670,"activeCount":12},[],{"trials":672,"activeCount":12},[],{"trials":674,"activeCount":32,"soonestReadout":192},[675,679],{"nctId":416,"briefTitle":417,"status":190,"phases":676,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":677,"interventions":678},[86],[18],[363,412,425,426,427],{"nctId":429,"briefTitle":430,"status":190,"phases":680,"primaryCompletion":192,"completion":255,"start":303,"enrollment":432,"conditions":681,"interventions":682},[86],[434,435],[363,411,427,437,426,412],{"trials":684,"activeCount":12},[],{"trials":686,"activeCount":12},[],{"intervention":323,"totalTrials":32,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":699,"PHASE4":705,"NA":707},{"trials":690,"activeCount":12},[],{"trials":692,"activeCount":12},[],{"trials":694,"activeCount":357,"soonestReadout":54},[695],{"nctId":52,"briefTitle":53,"status":190,"phases":696,"primaryCompletion":54,"completion":54,"start":318,"enrollment":319,"conditions":697,"interventions":698},[85],[321],[40,323],{"trials":700,"activeCount":357,"soonestReadout":350},[701],{"nctId":347,"briefTitle":348,"status":190,"phases":702,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":703,"interventions":704},[86],[26],[40,356],{"trials":706,"activeCount":12},[],{"trials":708,"activeCount":12},[],{"intervention":411,"totalTrials":32,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":721,"PHASE4":727,"NA":729},{"trials":712,"activeCount":12},[],{"trials":714,"activeCount":12},[],{"trials":716,"activeCount":357,"soonestReadout":405},[717],{"nctId":402,"briefTitle":403,"status":190,"phases":718,"primaryCompletion":405,"completion":405,"start":406,"enrollment":205,"conditions":719,"interventions":720},[84,85],[408],[410,400,363,411,412],{"trials":722,"activeCount":357,"soonestReadout":192},[723],{"nctId":429,"briefTitle":430,"status":190,"phases":724,"primaryCompletion":192,"completion":255,"start":303,"enrollment":432,"conditions":725,"interventions":726},[86],[434,435],[363,411,427,437,426,412],{"trials":728,"activeCount":12},[],{"trials":730,"activeCount":12},[],{"intervention":238,"totalTrials":32,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":749,"NA":751},{"trials":734,"activeCount":12},[],{"trials":736,"activeCount":12},[],{"trials":738,"activeCount":12},[],{"trials":740,"activeCount":357,"soonestReadout":72},[741,745],{"nctId":70,"briefTitle":71,"status":169,"phases":742,"primaryCompletion":72,"completion":72,"start":234,"enrollment":235,"conditions":743,"interventions":744},[86],[160,159],[45,238],{"nctId":240,"briefTitle":241,"status":100,"phases":746,"primaryCompletion":243,"completion":244,"start":245,"enrollment":246,"conditions":747,"interventions":748},[86],[15],[45,45,45,249],{"trials":750,"activeCount":12},[],{"trials":752,"activeCount":12},[],{"intervention":506,"totalTrials":32,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":765,"PHASE4":771,"NA":773},{"trials":756,"activeCount":12},[],{"trials":758,"activeCount":12},[],{"trials":760,"activeCount":12},[761],{"nctId":496,"briefTitle":497,"status":100,"phases":762,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":763,"interventions":764},[84,85],[504],[59,467,506],{"trials":766,"activeCount":357,"soonestReadout":58},[767],{"nctId":56,"briefTitle":57,"status":190,"phases":768,"primaryCompletion":58,"completion":511,"start":512,"enrollment":513,"conditions":769,"interventions":770},[85,86],[515],[59,517,506],{"trials":772,"activeCount":12},[],{"trials":774,"activeCount":12},[],{"intervention":425,"totalTrials":357,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":789,"NA":791},{"trials":778,"activeCount":12},[],{"trials":780,"activeCount":12},[],{"trials":782,"activeCount":12},[],{"trials":784,"activeCount":357,"soonestReadout":419},[785],{"nctId":416,"briefTitle":417,"status":190,"phases":786,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":787,"interventions":788},[86],[18],[363,412,425,426,427],{"trials":790,"activeCount":12},[],{"trials":792,"activeCount":12},[],{"intervention":794,"totalTrials":357,"cells":795},"HRS-8080 Tablet ; Dalpiciclib Isethionate",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":815,"NA":817},{"trials":797,"activeCount":12},[],{"trials":799,"activeCount":12},[],{"trials":801,"activeCount":12},[],{"trials":803,"activeCount":357,"soonestReadout":405},[804],{"nctId":805,"briefTitle":806,"status":190,"phases":807,"primaryCompletion":405,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":813},"NCT07354022","A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.",[86],"2031-12","2026-05-05",912,[812],"Locally Advanced or Metastatic Breast Cancer",[794,814],"Fulvestrant injection ;Dalpiciclib Isethionate",{"trials":816,"activeCount":12},[],{"trials":818,"activeCount":12},[],{"intervention":814,"totalTrials":357,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":833,"NA":835},{"trials":822,"activeCount":12},[],{"trials":824,"activeCount":12},[],{"trials":826,"activeCount":12},[],{"trials":828,"activeCount":357,"soonestReadout":405},[829],{"nctId":805,"briefTitle":806,"status":190,"phases":830,"primaryCompletion":405,"completion":808,"start":809,"enrollment":810,"conditions":831,"interventions":832},[86],[812],[794,814],{"trials":834,"activeCount":12},[],{"trials":836,"activeCount":12},[],{"intervention":589,"totalTrials":357,"cells":838},{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":851,"NA":853},{"trials":840,"activeCount":12},[],{"trials":842,"activeCount":12},[],{"trials":844,"activeCount":12},[],{"trials":846,"activeCount":357,"soonestReadout":583},[847],{"nctId":580,"briefTitle":581,"status":253,"phases":848,"primaryCompletion":583,"completion":584,"start":76,"enrollment":585,"conditions":849,"interventions":850},[86],[587],[549,589,590,591],{"trials":852,"activeCount":12},[],{"trials":854,"activeCount":12},[],{"intervention":590,"totalTrials":357,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":869,"NA":871},{"trials":858,"activeCount":12},[],{"trials":860,"activeCount":12},[],{"trials":862,"activeCount":12},[],{"trials":864,"activeCount":357,"soonestReadout":583},[865],{"nctId":580,"briefTitle":581,"status":253,"phases":866,"primaryCompletion":583,"completion":584,"start":76,"enrollment":585,"conditions":867,"interventions":868},[86],[587],[549,589,590,591],{"trials":870,"activeCount":12},[],{"trials":872,"activeCount":12},[],{"intervention":591,"totalTrials":357,"cells":874},{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":887,"NA":889},{"trials":876,"activeCount":12},[],{"trials":878,"activeCount":12},[],{"trials":880,"activeCount":12},[],{"trials":882,"activeCount":357,"soonestReadout":583},[883],{"nctId":580,"briefTitle":581,"status":253,"phases":884,"primaryCompletion":583,"completion":584,"start":76,"enrollment":585,"conditions":885,"interventions":886},[86],[587],[549,589,590,591],{"trials":888,"activeCount":12},[],{"trials":890,"activeCount":12},[],{"intervention":517,"totalTrials":357,"cells":892},{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":905,"NA":907},{"trials":894,"activeCount":12},[],{"trials":896,"activeCount":12},[],{"trials":898,"activeCount":12},[],{"trials":900,"activeCount":357,"soonestReadout":58},[901],{"nctId":56,"briefTitle":57,"status":190,"phases":902,"primaryCompletion":58,"completion":511,"start":512,"enrollment":513,"conditions":903,"interventions":904},[85,86],[515],[59,517,506],{"trials":906,"activeCount":12},[],{"trials":908,"activeCount":12},[],{"intervention":437,"totalTrials":357,"cells":910},{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":923,"NA":925},{"trials":912,"activeCount":12},[],{"trials":914,"activeCount":12},[],{"trials":916,"activeCount":12},[],{"trials":918,"activeCount":357,"soonestReadout":192},[919],{"nctId":429,"briefTitle":430,"status":190,"phases":920,"primaryCompletion":192,"completion":255,"start":303,"enrollment":432,"conditions":921,"interventions":922},[86],[434,435],[363,411,427,437,426,412],{"trials":924,"activeCount":12},[],{"trials":926,"activeCount":12},[],{"intervention":268,"totalTrials":357,"cells":928},{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":941,"NA":943},{"trials":930,"activeCount":12},[],{"trials":932,"activeCount":12},[],{"trials":934,"activeCount":12},[],{"trials":936,"activeCount":357,"soonestReadout":63},[937],{"nctId":61,"briefTitle":62,"status":190,"phases":938,"primaryCompletion":63,"completion":263,"start":264,"enrollment":265,"conditions":939,"interventions":940},[86],[15],[45,268],{"trials":942,"activeCount":12},[],{"trials":944,"activeCount":12},[],{"intervention":946,"totalTrials":947,"cells":948},"HRS-1301",5,{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":988,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":950,"activeCount":12},[],{"trials":952,"activeCount":32,"soonestReadout":483},[953,962,972,980],{"nctId":954,"briefTitle":955,"status":100,"phases":956,"primaryCompletion":352,"completion":352,"start":957,"enrollment":958,"conditions":959,"interventions":960},"NCT06857253","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1301 in Healthy Subjects",[84],"2025-03-18",82,[28],[946,961],"HRS-1301 placebo",{"nctId":963,"briefTitle":964,"status":190,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":971},"NCT07322016","A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function",[84],"2026-10","2026-01-13",36,[970],"Hyperlipidemias",[946],{"nctId":973,"briefTitle":974,"status":100,"phases":975,"primaryCompletion":976,"completion":976,"start":977,"enrollment":91,"conditions":978,"interventions":979},"NCT07097831","A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects",[84],"2025-11-07","2025-10-09",[28],[946,164],{"nctId":981,"briefTitle":982,"status":253,"phases":983,"primaryCompletion":483,"completion":483,"start":76,"enrollment":91,"conditions":984,"interventions":985},"NCT07608705","A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants",[84],[970],[946,986,987],"Atorvastatin Calcium","Midazolam oral solution",{"trials":989,"activeCount":357,"soonestReadout":483},[990],{"nctId":991,"briefTitle":992,"status":190,"phases":993,"primaryCompletion":483,"completion":483,"start":994,"enrollment":995,"conditions":996,"interventions":997},"NCT07229937","A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia",[85],"2025-11-25",189,[28],[946,946,946,946],{"trials":999,"activeCount":12},[],{"trials":1001,"activeCount":12},[],{"trials":1003,"activeCount":12},[],{"intervention":50,"totalTrials":32,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1016,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1007,"activeCount":12},[],{"trials":1009,"activeCount":357,"soonestReadout":49},[1010],{"nctId":47,"briefTitle":48,"status":190,"phases":1011,"primaryCompletion":49,"completion":171,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},[84],"2023-02-07",102,[18],[50],{"trials":1017,"activeCount":357,"soonestReadout":392},[1018],{"nctId":389,"briefTitle":390,"status":190,"phases":1019,"primaryCompletion":392,"completion":393,"start":394,"enrollment":329,"conditions":1020,"interventions":1021},[84,85],[396],[398,399,363,400,50],{"trials":1023,"activeCount":12},[],{"trials":1025,"activeCount":12},[],{"trials":1027,"activeCount":12},[],{"intervention":400,"totalTrials":32,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1031,"activeCount":12},[],{"trials":1033,"activeCount":12},[],{"trials":1035,"activeCount":32,"soonestReadout":392},[1036,1040],{"nctId":389,"briefTitle":390,"status":190,"phases":1037,"primaryCompletion":392,"completion":393,"start":394,"enrollment":329,"conditions":1038,"interventions":1039},[84,85],[396],[398,399,363,400,50],{"nctId":402,"briefTitle":403,"status":190,"phases":1041,"primaryCompletion":405,"completion":405,"start":406,"enrollment":205,"conditions":1042,"interventions":1043},[84,85],[408],[410,400,363,411,412],{"trials":1045,"activeCount":12},[],{"trials":1047,"activeCount":12},[],{"trials":1049,"activeCount":12},[],{"intervention":410,"totalTrials":32,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1065,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1053,"activeCount":12},[],{"trials":1055,"activeCount":357,"soonestReadout":1060},[1056],{"nctId":1057,"briefTitle":1058,"status":190,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1064},"NCT06727812","Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors",[84],"2027-08","2024-12-17",206,[566],[410],{"trials":1066,"activeCount":357,"soonestReadout":405},[1067],{"nctId":402,"briefTitle":403,"status":190,"phases":1068,"primaryCompletion":405,"completion":405,"start":406,"enrollment":205,"conditions":1069,"interventions":1070},[84,85],[408],[410,400,363,411,412],{"trials":1072,"activeCount":12},[],{"trials":1074,"activeCount":12},[],{"trials":1076,"activeCount":12},[],{"intervention":398,"totalTrials":32,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1091,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1080,"activeCount":12},[],{"trials":1082,"activeCount":12},[1083],{"nctId":1084,"briefTitle":1085,"status":142,"phases":1086,"primaryCompletion":373,"completion":373,"start":1087,"enrollment":623,"conditions":1088,"interventions":1090},"NCT05851092","Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors",[84],"2023-05-26",[1089],"Advanced Malignant Tumor",[398],{"trials":1092,"activeCount":357,"soonestReadout":392},[1093],{"nctId":389,"briefTitle":390,"status":190,"phases":1094,"primaryCompletion":392,"completion":393,"start":394,"enrollment":329,"conditions":1095,"interventions":1096},[84,85],[396],[398,399,363,400,50],{"trials":1098,"activeCount":12},[],{"trials":1100,"activeCount":12},[],{"trials":1102,"activeCount":12},[],{"intervention":1104,"totalTrials":32,"cells":1105},"HRS-7085",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1122,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1107,"activeCount":12},[],{"trials":1109,"activeCount":12},[1110],{"nctId":1111,"briefTitle":1112,"status":142,"phases":1113,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":1117,"conditions":1118,"interventions":1120},"NCT06175949","A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects",[84],"2024-06","2024-07","2023-12",70,[1119],"Inflammatory Bowel Disease",[1104,1121],"HRS-7085 simulant",{"trials":1123,"activeCount":357,"soonestReadout":192},[1124],{"nctId":1125,"briefTitle":1126,"status":190,"phases":1127,"primaryCompletion":192,"completion":192,"start":1128,"enrollment":339,"conditions":1129,"interventions":1131},"NCT07229950","A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease",[85],"2025-10-17",[1130],"Adult Patients With Moderately to Severely Active Ulcerative Colitis",[1104,1104],{"trials":1133,"activeCount":12},[],{"trials":1135,"activeCount":12},[],{"trials":1137,"activeCount":12},[],{"intervention":1139,"totalTrials":357,"cells":1140},"HRS-7058 + SHR-1316",{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1142,"activeCount":12},[],{"trials":1144,"activeCount":12},[],{"trials":1146,"activeCount":357,"soonestReadout":192},[1147],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1150,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1153,"interventions":1154},"NCT06915142","A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour",[85],"2027-10","2025-04-28",[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],"HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy","HRS-7058 + Cetuximab","HRS-7058 + SHR-1826","HRS-7058 + SHR-1826 + SHR-1316","HRS-7058 + SHR-A1202","HRS-7058 + BP102","HRS-7058 + SHR-9839","HRS-7058 +SHR-A2102 +SHR-1316","HRS-7058 +SHR-9839(sc)+SHR-1316","HRS-7058 +SHR-1316 +BP102","HRS-7058 +SHR-A2102 +BP102","HRS-7058 +SHR-A2102 +SHR-1316 +BP102",{"trials":1168,"activeCount":12},[],{"trials":1170,"activeCount":12},[],{"trials":1172,"activeCount":12},[],{"intervention":1155,"totalTrials":357,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1176,"activeCount":12},[],{"trials":1178,"activeCount":12},[],{"trials":1180,"activeCount":357,"soonestReadout":192},[1181],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1182,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1183,"interventions":1184},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1186,"activeCount":12},[],{"trials":1188,"activeCount":12},[],{"trials":1190,"activeCount":12},[],{"intervention":1156,"totalTrials":357,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1194,"activeCount":12},[],{"trials":1196,"activeCount":12},[],{"trials":1198,"activeCount":357,"soonestReadout":192},[1199],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1200,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1201,"interventions":1202},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1204,"activeCount":12},[],{"trials":1206,"activeCount":12},[],{"trials":1208,"activeCount":12},[],{"intervention":1157,"totalTrials":357,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1212,"activeCount":12},[],{"trials":1214,"activeCount":12},[],{"trials":1216,"activeCount":357,"soonestReadout":192},[1217],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1218,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1219,"interventions":1220},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1222,"activeCount":12},[],{"trials":1224,"activeCount":12},[],{"trials":1226,"activeCount":12},[],{"intervention":1158,"totalTrials":357,"cells":1228},{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1239,"PHASE4":1241,"NA":1243},{"trials":1230,"activeCount":12},[],{"trials":1232,"activeCount":12},[],{"trials":1234,"activeCount":357,"soonestReadout":192},[1235],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1236,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1237,"interventions":1238},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1240,"activeCount":12},[],{"trials":1242,"activeCount":12},[],{"trials":1244,"activeCount":12},[],{"intervention":1159,"totalTrials":357,"cells":1246},{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1257,"PHASE4":1259,"NA":1261},{"trials":1248,"activeCount":12},[],{"trials":1250,"activeCount":12},[],{"trials":1252,"activeCount":357,"soonestReadout":192},[1253],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1254,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1255,"interventions":1256},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1258,"activeCount":12},[],{"trials":1260,"activeCount":12},[],{"trials":1262,"activeCount":12},[],{"intervention":1160,"totalTrials":357,"cells":1264},{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1266,"activeCount":12},[],{"trials":1268,"activeCount":12},[],{"trials":1270,"activeCount":357,"soonestReadout":192},[1271],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1272,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1273,"interventions":1274},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1276,"activeCount":12},[],{"trials":1278,"activeCount":12},[],{"trials":1280,"activeCount":12},[],{"intervention":1161,"totalTrials":357,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1284,"activeCount":12},[],{"trials":1286,"activeCount":12},[],{"trials":1288,"activeCount":357,"soonestReadout":192},[1289],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1290,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1291,"interventions":1292},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1294,"activeCount":12},[],{"trials":1296,"activeCount":12},[],{"trials":1298,"activeCount":12},[],{"intervention":1162,"totalTrials":357,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1302,"activeCount":12},[],{"trials":1304,"activeCount":12},[],{"trials":1306,"activeCount":357,"soonestReadout":192},[1307],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1308,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1309,"interventions":1310},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1312,"activeCount":12},[],{"trials":1314,"activeCount":12},[],{"trials":1316,"activeCount":12},[],{"intervention":1163,"totalTrials":357,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1320,"activeCount":12},[],{"trials":1322,"activeCount":12},[],{"trials":1324,"activeCount":357,"soonestReadout":192},[1325],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1326,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1327,"interventions":1328},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1330,"activeCount":12},[],{"trials":1332,"activeCount":12},[],{"trials":1334,"activeCount":12},[],{"intervention":1164,"totalTrials":357,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1338,"activeCount":12},[],{"trials":1340,"activeCount":12},[],{"trials":1342,"activeCount":357,"soonestReadout":192},[1343],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1344,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1345,"interventions":1346},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1348,"activeCount":12},[],{"trials":1350,"activeCount":12},[],{"trials":1352,"activeCount":12},[],{"intervention":1165,"totalTrials":357,"cells":1354},{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1365,"PHASE4":1367,"NA":1369},{"trials":1356,"activeCount":12},[],{"trials":1358,"activeCount":12},[],{"trials":1360,"activeCount":357,"soonestReadout":192},[1361],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1362,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1363,"interventions":1364},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1366,"activeCount":12},[],{"trials":1368,"activeCount":12},[],{"trials":1370,"activeCount":12},[],{"intervention":1166,"totalTrials":357,"cells":1372},{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1383,"PHASE4":1385,"NA":1387},{"trials":1374,"activeCount":12},[],{"trials":1376,"activeCount":12},[],{"trials":1378,"activeCount":357,"soonestReadout":192},[1379],{"nctId":1148,"briefTitle":1149,"status":190,"phases":1380,"primaryCompletion":192,"completion":1151,"start":1152,"enrollment":329,"conditions":1381,"interventions":1382},[85],[34],[1139,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],{"trials":1384,"activeCount":12},[],{"trials":1386,"activeCount":12},[],{"trials":1388,"activeCount":12},[],{"intervention":399,"totalTrials":357,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1401,"PHASE4":1403,"NA":1405},{"trials":1392,"activeCount":12},[],{"trials":1394,"activeCount":12},[],{"trials":1396,"activeCount":357,"soonestReadout":392},[1397],{"nctId":389,"briefTitle":390,"status":190,"phases":1398,"primaryCompletion":392,"completion":393,"start":394,"enrollment":329,"conditions":1399,"interventions":1400},[84,85],[396],[398,399,363,400,50],{"trials":1402,"activeCount":12},[],{"trials":1404,"activeCount":12},[],{"trials":1406,"activeCount":12},[],{"intervention":1408,"totalTrials":357,"cells":1409},"HRS-8080; SHR-A1811",{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1427,"PHASE4":1429,"NA":1431},{"trials":1411,"activeCount":12},[],{"trials":1413,"activeCount":12},[],{"trials":1415,"activeCount":357,"soonestReadout":1420},[1416],{"nctId":1417,"briefTitle":1418,"status":190,"phases":1419,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1424},"NCT06222879","Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer",[84,85],"2026-10-31","2024-02-20",350,[18],[1408,1425,1426],"HRS-8080; SHR-A2009","SHR-A2009; SHR-1316",{"trials":1428,"activeCount":12},[],{"trials":1430,"activeCount":12},[],{"trials":1432,"activeCount":12},[],{"intervention":1425,"totalTrials":357,"cells":1434},{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1436,"activeCount":12},[],{"trials":1438,"activeCount":12},[],{"trials":1440,"activeCount":357,"soonestReadout":1420},[1441],{"nctId":1417,"briefTitle":1418,"status":190,"phases":1442,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":1443,"interventions":1444},[84,85],[18],[1408,1425,1426],{"trials":1446,"activeCount":12},[],{"trials":1448,"activeCount":12},[],{"trials":1450,"activeCount":12},[],{"intervention":1426,"totalTrials":357,"cells":1452},{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1454,"activeCount":12},[],{"trials":1456,"activeCount":12},[],{"trials":1458,"activeCount":357,"soonestReadout":1420},[1459],{"nctId":1417,"briefTitle":1418,"status":190,"phases":1460,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":1461,"interventions":1462},[84,85],[18],[1408,1425,1426],{"trials":1464,"activeCount":12},[],{"trials":1466,"activeCount":12},[],{"trials":1468,"activeCount":12},[],{"intervention":77,"totalTrials":357,"cells":1470},{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1484,"PHASE4":1486,"NA":1488},{"trials":1472,"activeCount":12},[],{"trials":1474,"activeCount":12},[],{"trials":1476,"activeCount":357,"soonestReadout":76},[1477],{"nctId":74,"briefTitle":75,"status":190,"phases":1478,"primaryCompletion":76,"completion":76,"start":1479,"enrollment":1480,"conditions":1481,"interventions":1483},[84,85],"2023-12-20",146,[1482],"Unresectable or Metastatic Breast Cancer",[77],{"trials":1485,"activeCount":12},[],{"trials":1487,"activeCount":12},[],{"trials":1489,"activeCount":12},[],{"intervention":1491,"totalTrials":357,"cells":1492},"HRS-6719",{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1497,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1494,"activeCount":12},[],{"trials":1496,"activeCount":12},[],{"trials":1498,"activeCount":357,"soonestReadout":255},[1499],{"nctId":1500,"briefTitle":1501,"status":190,"phases":1502,"primaryCompletion":255,"completion":255,"start":1503,"enrollment":1504,"conditions":1505,"interventions":1507},"NCT06922357","A Phase I\u002FII of HRS-6719 in Patients With Advanced\u002FMetastatic Solid Tumors",[84,85],"2025-04-24",120,[1506],"Advanced\u002FMetastatic Solid Tumors",[1491],{"trials":1509,"activeCount":12},[],{"trials":1511,"activeCount":12},[],{"trials":1513,"activeCount":12},[],{"intervention":198,"totalTrials":357,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1517,"activeCount":12},[],{"trials":1519,"activeCount":12},[],{"trials":1521,"activeCount":357,"soonestReadout":192},[1522],{"nctId":188,"briefTitle":189,"status":190,"phases":1523,"primaryCompletion":192,"completion":192,"start":193,"enrollment":194,"conditions":1524,"interventions":1525},[85],[196],[45,198],{"trials":1527,"activeCount":12},[],{"trials":1529,"activeCount":12},[],{"trials":1531,"activeCount":12},[],{"intervention":343,"totalTrials":357,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":12},[],{"trials":1537,"activeCount":12},[],{"trials":1539,"activeCount":357,"soonestReadout":336},[1540],{"nctId":333,"briefTitle":334,"status":190,"phases":1541,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":1542,"interventions":1543},[85],[341],[40,343],{"trials":1545,"activeCount":12},[],{"trials":1547,"activeCount":12},[],{"trials":1549,"activeCount":12},[],{"intervention":457,"totalTrials":22,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1568,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1553,"activeCount":12},[],{"trials":1555,"activeCount":357,"soonestReadout":350},[1556,1560,1564],{"nctId":449,"briefTitle":450,"status":100,"phases":1557,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":1558,"interventions":1559},[84],[31],[59,457],{"nctId":459,"briefTitle":460,"status":100,"phases":1561,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":1562,"interventions":1563},[84],[31],[59,467],{"nctId":469,"briefTitle":470,"status":190,"phases":1565,"primaryCompletion":350,"completion":351,"start":472,"enrollment":473,"conditions":1566,"interventions":1567},[84],[475],[59,457,477,478],{"trials":1569,"activeCount":12},[1570],{"nctId":496,"briefTitle":497,"status":100,"phases":1571,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":1572,"interventions":1573},[84,85],[504],[59,467,506],{"trials":1575,"activeCount":12},[],{"trials":1577,"activeCount":12},[],{"trials":1579,"activeCount":12},[],{"intervention":477,"totalTrials":357,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1590,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1583,"activeCount":12},[],{"trials":1585,"activeCount":357,"soonestReadout":350},[1586],{"nctId":469,"briefTitle":470,"status":190,"phases":1587,"primaryCompletion":350,"completion":351,"start":472,"enrollment":473,"conditions":1588,"interventions":1589},[84],[475],[59,457,477,478],{"trials":1591,"activeCount":12},[],{"trials":1593,"activeCount":12},[],{"trials":1595,"activeCount":12},[],{"trials":1597,"activeCount":12},[],{"intervention":478,"totalTrials":357,"cells":1599},{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1608,"PHASE3":1610,"PHASE4":1612,"NA":1614},{"trials":1601,"activeCount":12},[],{"trials":1603,"activeCount":357,"soonestReadout":350},[1604],{"nctId":469,"briefTitle":470,"status":190,"phases":1605,"primaryCompletion":350,"completion":351,"start":472,"enrollment":473,"conditions":1606,"interventions":1607},[84],[475],[59,457,477,478],{"trials":1609,"activeCount":12},[],{"trials":1611,"activeCount":12},[],{"trials":1613,"activeCount":12},[],{"trials":1615,"activeCount":12},[],{"intervention":490,"totalTrials":357,"cells":1617},{"EARLY_PHASE1":1618,"PHASE1":1620,"PHASE2":1626,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1619,"activeCount":12},[],{"trials":1621,"activeCount":357,"soonestReadout":483},[1622],{"nctId":480,"briefTitle":481,"status":190,"phases":1623,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":1624,"interventions":1625},[84],[487,488],[59,490,491,492],{"trials":1627,"activeCount":12},[],{"trials":1629,"activeCount":12},[],{"trials":1631,"activeCount":12},[],{"trials":1633,"activeCount":12},[],{"intervention":491,"totalTrials":357,"cells":1635},{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1644,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1637,"activeCount":12},[],{"trials":1639,"activeCount":357,"soonestReadout":483},[1640],{"nctId":480,"briefTitle":481,"status":190,"phases":1641,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":1642,"interventions":1643},[84],[487,488],[59,490,491,492],{"trials":1645,"activeCount":12},[],{"trials":1647,"activeCount":12},[],{"trials":1649,"activeCount":12},[],{"trials":1651,"activeCount":12},[],{"intervention":492,"totalTrials":357,"cells":1653},{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1662,"PHASE3":1664,"PHASE4":1666,"NA":1668},{"trials":1655,"activeCount":12},[],{"trials":1657,"activeCount":357,"soonestReadout":483},[1658],{"nctId":480,"briefTitle":481,"status":190,"phases":1659,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":1660,"interventions":1661},[84],[487,488],[59,490,491,492],{"trials":1663,"activeCount":12},[],{"trials":1665,"activeCount":12},[],{"trials":1667,"activeCount":12},[],{"trials":1669,"activeCount":12},[],{"intervention":986,"totalTrials":357,"cells":1671},{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1680,"PHASE3":1682,"PHASE4":1684,"NA":1686},{"trials":1673,"activeCount":12},[],{"trials":1675,"activeCount":357,"soonestReadout":483},[1676],{"nctId":981,"briefTitle":982,"status":253,"phases":1677,"primaryCompletion":483,"completion":483,"start":76,"enrollment":91,"conditions":1678,"interventions":1679},[84],[970],[946,986,987],{"trials":1681,"activeCount":12},[],{"trials":1683,"activeCount":12},[],{"trials":1685,"activeCount":12},[],{"trials":1687,"activeCount":12},[],{"intervention":987,"totalTrials":357,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1698,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1691,"activeCount":12},[],{"trials":1693,"activeCount":357,"soonestReadout":483},[1694],{"nctId":981,"briefTitle":982,"status":253,"phases":1695,"primaryCompletion":483,"completion":483,"start":76,"enrollment":91,"conditions":1696,"interventions":1697},[84],[970],[946,986,987],{"trials":1699,"activeCount":12},[],{"trials":1701,"activeCount":12},[],{"trials":1703,"activeCount":12},[],{"trials":1705,"activeCount":12},[],{"intervention":1707,"totalTrials":357,"cells":1708},"HRS-3802",{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1710,"activeCount":12},[],{"trials":1712,"activeCount":357,"soonestReadout":405},[1713],{"nctId":1714,"briefTitle":1715,"status":190,"phases":1716,"primaryCompletion":405,"completion":405,"start":394,"enrollment":564,"conditions":1717,"interventions":1719},"NCT06770569","A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors",[84],[1718],"Advanced Solid Tumors",[1707],{"trials":1721,"activeCount":12},[],{"trials":1723,"activeCount":12},[],{"trials":1725,"activeCount":12},[],{"trials":1727,"activeCount":12},[],{"intervention":81,"totalTrials":357,"cells":1729},{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1739,"PHASE3":1741,"PHASE4":1743,"NA":1745},{"trials":1731,"activeCount":12},[],{"trials":1733,"activeCount":357,"soonestReadout":76},[1734],{"nctId":79,"briefTitle":80,"status":253,"phases":1735,"primaryCompletion":76,"completion":76,"start":72,"enrollment":19,"conditions":1736,"interventions":1738},[84],[1737],"Chronic Kidney Diseases",[81],{"trials":1740,"activeCount":12},[],{"trials":1742,"activeCount":12},[],{"trials":1744,"activeCount":12},[],{"trials":1746,"activeCount":12},[],{"intervention":1748,"totalTrials":357,"cells":1749},"HRS-7058 capsule\u002F HRS-7058",{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1762,"PHASE3":1764,"PHASE4":1766,"NA":1768},{"trials":1751,"activeCount":12},[],{"trials":1753,"activeCount":357,"soonestReadout":76},[1754],{"nctId":1755,"briefTitle":1756,"status":190,"phases":1757,"primaryCompletion":76,"completion":76,"start":1758,"enrollment":1759,"conditions":1760,"interventions":1761},"NCT06383871","A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour",[84],"2024-06-06",233,[34],[1748],{"trials":1763,"activeCount":12},[],{"trials":1765,"activeCount":12},[],{"trials":1767,"activeCount":12},[],{"trials":1769,"activeCount":12},[],{"intervention":1771,"totalTrials":357,"cells":1772},"HRS-7156",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1787,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1774,"activeCount":12},[],{"trials":1776,"activeCount":357,"soonestReadout":1781},[1777],{"nctId":1778,"briefTitle":1779,"status":253,"phases":1780,"primaryCompletion":1781,"completion":1781,"start":72,"enrollment":1782,"conditions":1783,"interventions":1785},"NCT07601087","A Clinical Study of HRS-7156 in Healthy Participants",[84],"2026-07",66,[1784],"Heart Failure",[1771,1786],"HRS-7156 placebo",{"trials":1788,"activeCount":12},[],{"trials":1790,"activeCount":12},[],{"trials":1792,"activeCount":12},[],{"trials":1794,"activeCount":12},[],{"intervention":1786,"totalTrials":357,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1805,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1798,"activeCount":12},[],{"trials":1800,"activeCount":357,"soonestReadout":1781},[1801],{"nctId":1778,"briefTitle":1779,"status":253,"phases":1802,"primaryCompletion":1781,"completion":1781,"start":72,"enrollment":1782,"conditions":1803,"interventions":1804},[84],[1784],[1771,1786],{"trials":1806,"activeCount":12},[],{"trials":1808,"activeCount":12},[],{"trials":1810,"activeCount":12},[],{"trials":1812,"activeCount":12},[],{"intervention":1814,"totalTrials":357,"cells":1815},"Test formulation of HRS-1893",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1829,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1817,"activeCount":12},[],{"trials":1819,"activeCount":357,"soonestReadout":76},[1820],{"nctId":1821,"briefTitle":1822,"status":190,"phases":1823,"primaryCompletion":76,"completion":1781,"start":1824,"enrollment":968,"conditions":1825,"interventions":1827},"NCT07479641","A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants",[84],"2026-04-14",[1826],"Cardiomyopathy",[1814,1828],"Reference formulation of HRS-1893",{"trials":1830,"activeCount":12},[],{"trials":1832,"activeCount":12},[],{"trials":1834,"activeCount":12},[],{"trials":1836,"activeCount":12},[],{"intervention":1828,"totalTrials":357,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1847,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1840,"activeCount":12},[],{"trials":1842,"activeCount":357,"soonestReadout":76},[1843],{"nctId":1821,"briefTitle":1822,"status":190,"phases":1844,"primaryCompletion":76,"completion":1781,"start":1824,"enrollment":968,"conditions":1845,"interventions":1846},[84],[1826],[1814,1828],{"trials":1848,"activeCount":12},[],{"trials":1850,"activeCount":12},[],{"trials":1852,"activeCount":12},[],{"trials":1854,"activeCount":12},[],{"intervention":68,"totalTrials":357,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1865,"PHASE3":1867,"PHASE4":1869,"NA":1871},{"trials":1858,"activeCount":12},[],{"trials":1860,"activeCount":357,"soonestReadout":67},[1861],{"nctId":65,"briefTitle":66,"status":253,"phases":1862,"primaryCompletion":67,"completion":67,"start":511,"enrollment":19,"conditions":1863,"interventions":1864},[84],[18],[68],{"trials":1866,"activeCount":12},[],{"trials":1868,"activeCount":12},[],{"trials":1870,"activeCount":12},[],{"trials":1872,"activeCount":12},[],{"intervention":1874,"totalTrials":32,"cells":1875},"HRS-5346",{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1890,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1877,"activeCount":12},[],{"trials":1879,"activeCount":12},[1880],{"nctId":1881,"briefTitle":1882,"status":100,"phases":1883,"primaryCompletion":1884,"completion":1884,"start":1885,"enrollment":1886,"conditions":1887,"interventions":1889},"NCT06441227","Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects",[84],"2025-01-09","2024-06-13",71,[1888],"Lipoprotein Disorder Disease",[1874],{"trials":1891,"activeCount":12},[1892],{"nctId":1893,"briefTitle":1894,"status":100,"phases":1895,"primaryCompletion":1896,"completion":1896,"start":1897,"enrollment":1504,"conditions":1898,"interventions":1900},"NCT06816264","A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events",[85],"2025-09-29","2025-02-18",[1899],"Treatment of Lipoprotein Disorder",[1874],{"trials":1902,"activeCount":12},[],{"trials":1904,"activeCount":12},[],{"trials":1906,"activeCount":12},[],{"intervention":1908,"totalTrials":357,"cells":1909},"HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1926,"PHASE4":1928,"NA":1930},{"trials":1911,"activeCount":12},[],{"trials":1913,"activeCount":12},[],{"trials":1915,"activeCount":12},[1916],{"nctId":1917,"briefTitle":1918,"status":100,"phases":1919,"primaryCompletion":1920,"completion":1921,"start":1922,"enrollment":1923,"conditions":1924,"interventions":1925},"NCT06221059","Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease",[85],"2025-03-05","2025-06-24","2024-03-02",181,[24],[1908],{"trials":1927,"activeCount":12},[],{"trials":1929,"activeCount":12},[],{"trials":1931,"activeCount":12},[],{"intervention":1933,"totalTrials":357,"cells":1934},"HRS-7535;Placebo",{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1936,"activeCount":12},[],{"trials":1938,"activeCount":12},[],{"trials":1940,"activeCount":12},[1941],{"nctId":1942,"briefTitle":1943,"status":100,"phases":1944,"primaryCompletion":1945,"completion":1945,"start":1946,"enrollment":1947,"conditions":1948,"interventions":1950},"NCT06250946","Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .",[85],"2025-01-22","2024-02-23",235,[1949],"Overweight and Obesity",[1933],{"trials":1952,"activeCount":12},[],{"trials":1954,"activeCount":12},[],{"trials":1956,"activeCount":12},[],{"intervention":164,"totalTrials":32,"cells":1958},{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1971,"PHASE3":1973,"PHASE4":1975,"NA":1977},{"trials":1960,"activeCount":12},[],{"trials":1962,"activeCount":12},[1963,1967],{"nctId":973,"briefTitle":974,"status":100,"phases":1964,"primaryCompletion":976,"completion":976,"start":977,"enrollment":91,"conditions":1965,"interventions":1966},[84],[28],[946,164],{"nctId":152,"briefTitle":153,"status":100,"phases":1968,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":1969,"interventions":1970},[84],[159,160],[45,162,163,164,165],{"trials":1972,"activeCount":12},[],{"trials":1974,"activeCount":12},[],{"trials":1976,"activeCount":12},[],{"trials":1978,"activeCount":12},[],{"intervention":108,"totalTrials":357,"cells":1980},{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1989,"PHASE3":1991,"PHASE4":1993,"NA":1995},{"trials":1982,"activeCount":12},[],{"trials":1984,"activeCount":12},[1985],{"nctId":98,"briefTitle":99,"status":100,"phases":1986,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":1987,"interventions":1988},[84],[21],[107,108,45],{"trials":1990,"activeCount":12},[],{"trials":1992,"activeCount":12},[],{"trials":1994,"activeCount":12},[],{"trials":1996,"activeCount":12},[],{"intervention":961,"totalTrials":357,"cells":1998},{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2007,"PHASE3":2009,"PHASE4":2011,"NA":2013},{"trials":2000,"activeCount":12},[],{"trials":2002,"activeCount":12},[2003],{"nctId":954,"briefTitle":955,"status":100,"phases":2004,"primaryCompletion":352,"completion":352,"start":957,"enrollment":958,"conditions":2005,"interventions":2006},[84],[28],[946,961],{"trials":2008,"activeCount":12},[],{"trials":2010,"activeCount":12},[],{"trials":2012,"activeCount":12},[],{"trials":2014,"activeCount":12},[],{"intervention":119,"totalTrials":357,"cells":2016},{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2018,"activeCount":12},[],{"trials":2020,"activeCount":12},[2021],{"nctId":110,"briefTitle":111,"status":100,"phases":2022,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":2023,"interventions":2024},[84],[117],[45,119,120],{"trials":2026,"activeCount":12},[],{"trials":2028,"activeCount":12},[],{"trials":2030,"activeCount":12},[],{"trials":2032,"activeCount":12},[],{"intervention":120,"totalTrials":357,"cells":2034},{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2043,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2036,"activeCount":12},[],{"trials":2038,"activeCount":12},[2039],{"nctId":110,"briefTitle":111,"status":100,"phases":2040,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":2041,"interventions":2042},[84],[117],[45,119,120],{"trials":2044,"activeCount":12},[],{"trials":2046,"activeCount":12},[],{"trials":2048,"activeCount":12},[],{"trials":2050,"activeCount":12},[],{"intervention":2052,"totalTrials":357,"cells":2053},"HRS-1780 tablets; Itraconazole capsules; Rifampicin",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2055,"activeCount":12},[],{"trials":2057,"activeCount":12},[2058],{"nctId":2059,"briefTitle":2060,"status":142,"phases":2061,"primaryCompletion":1115,"completion":1115,"start":2062,"enrollment":2063,"conditions":2064,"interventions":2066},"NCT06344936","Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects",[84],"2024-04",28,[2065],"Chronic Kidney Disease(CKD)",[2052],{"trials":2068,"activeCount":12},[],{"trials":2070,"activeCount":12},[],{"trials":2072,"activeCount":12},[],{"trials":2074,"activeCount":12},[],{"intervention":377,"totalTrials":357,"cells":2076},{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2085,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2078,"activeCount":12},[],{"trials":2080,"activeCount":12},[2081],{"nctId":370,"briefTitle":371,"status":100,"phases":2082,"primaryCompletion":373,"completion":373,"start":374,"enrollment":91,"conditions":2083,"interventions":2084},[84],[18],[363,377],{"trials":2086,"activeCount":12},[],{"trials":2088,"activeCount":12},[],{"trials":2090,"activeCount":12},[],{"trials":2092,"activeCount":12},[],{"intervention":2094,"totalTrials":357,"cells":2095},"hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate",{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2109,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2097,"activeCount":12},[],{"trials":2099,"activeCount":12},[2100],{"nctId":2101,"briefTitle":2102,"status":100,"phases":2103,"primaryCompletion":2104,"completion":2104,"start":2105,"enrollment":6,"conditions":2106,"interventions":2107},"NCT05415644","Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy Subjects",[84],"2022-08-08","2022-07-05",[21],[2094,2108],"hrx0701",{"trials":2110,"activeCount":12},[],{"trials":2112,"activeCount":12},[],{"trials":2114,"activeCount":12},[],{"trials":2116,"activeCount":12},[],{"intervention":2108,"totalTrials":357,"cells":2118},{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2127,"PHASE3":2129,"PHASE4":2131,"NA":2133},{"trials":2120,"activeCount":12},[],{"trials":2122,"activeCount":12},[2123],{"nctId":2101,"briefTitle":2102,"status":100,"phases":2124,"primaryCompletion":2104,"completion":2104,"start":2105,"enrollment":6,"conditions":2125,"interventions":2126},[84],[21],[2094,2108],{"trials":2128,"activeCount":12},[],{"trials":2130,"activeCount":12},[],{"trials":2132,"activeCount":12},[],{"trials":2134,"activeCount":12},[],{"intervention":2136,"totalTrials":357,"cells":2137},"HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus",{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2153,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2139,"activeCount":12},[],{"trials":2141,"activeCount":12},[2142],{"nctId":2143,"briefTitle":2144,"status":142,"phases":2145,"primaryCompletion":2146,"completion":2147,"start":2148,"enrollment":2149,"conditions":2150,"interventions":2152},"NCT05189717","A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults",[84],"2024-10-31","2025-07-31","2022-02-17",156,[2151],"Metastatic or Local Advanced Breast Cancer of Patients",[2136],{"trials":2154,"activeCount":12},[],{"trials":2156,"activeCount":12},[],{"trials":2158,"activeCount":12},[],{"trials":2160,"activeCount":12},[],{"intervention":1121,"totalTrials":357,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2171,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2164,"activeCount":12},[],{"trials":2166,"activeCount":12},[2167],{"nctId":1111,"briefTitle":1112,"status":142,"phases":2168,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":1117,"conditions":2169,"interventions":2170},[84],[1119],[1104,1121],{"trials":2172,"activeCount":12},[],{"trials":2174,"activeCount":12},[],{"trials":2176,"activeCount":12},[],{"trials":2178,"activeCount":12},[],{"intervention":298,"totalTrials":357,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2182,"activeCount":12},[],{"trials":2184,"activeCount":12},[2185],{"nctId":290,"briefTitle":291,"status":100,"phases":2186,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":2187,"interventions":2188},[84],[26],[40,298],{"trials":2190,"activeCount":12},[],{"trials":2192,"activeCount":12},[],{"trials":2194,"activeCount":12},[],{"trials":2196,"activeCount":12},[],{"intervention":2198,"totalTrials":357,"cells":2199},"HRS-7535 Tables",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2213,"PHASE3":2215,"PHASE4":2217,"NA":2219},{"trials":2201,"activeCount":12},[],{"trials":2203,"activeCount":12},[2204],{"nctId":2205,"briefTitle":2206,"status":100,"phases":2207,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":104,"conditions":2210,"interventions":2212},"NCT06961643","Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function",[84],"2026-01-22","2025-06-05",[2211],"Diabetes Mellitus",[2198],{"trials":2214,"activeCount":12},[],{"trials":2216,"activeCount":12},[],{"trials":2218,"activeCount":12},[],{"trials":2220,"activeCount":12},[],{"intervention":2222,"totalTrials":357,"cells":2223},"HRS-1893 tablet A",{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2238,"PHASE3":2240,"PHASE4":2242,"NA":2244},{"trials":2225,"activeCount":12},[],{"trials":2227,"activeCount":12},[2228],{"nctId":2229,"briefTitle":2230,"status":100,"phases":2231,"primaryCompletion":2232,"completion":2232,"start":2233,"enrollment":2234,"conditions":2235,"interventions":2236},"NCT07272330","A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects",[84],"2026-03-21","2025-12-11",38,[1826],[2222,2237],"HRS-1893 tablet B",{"trials":2239,"activeCount":12},[],{"trials":2241,"activeCount":12},[],{"trials":2243,"activeCount":12},[],{"trials":2245,"activeCount":12},[],{"intervention":2237,"totalTrials":357,"cells":2247},{"EARLY_PHASE1":2248,"PHASE1":2250,"PHASE2":2256,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2249,"activeCount":12},[],{"trials":2251,"activeCount":12},[2252],{"nctId":2229,"briefTitle":2230,"status":100,"phases":2253,"primaryCompletion":2232,"completion":2232,"start":2233,"enrollment":2234,"conditions":2254,"interventions":2255},[84],[1826],[2222,2237],{"trials":2257,"activeCount":12},[],{"trials":2259,"activeCount":12},[],{"trials":2261,"activeCount":12},[],{"trials":2263,"activeCount":12},[],{"intervention":2265,"totalTrials":357,"cells":2266},"ARM A",{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2285,"PHASE3":2287,"PHASE4":2289,"NA":2291},{"trials":2268,"activeCount":12},[],{"trials":2270,"activeCount":12},[2271],{"nctId":2272,"briefTitle":2273,"status":100,"phases":2274,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":2277,"conditions":2278,"interventions":2279},"NCT05682495","A HR20031 BE Study on Healthy Subjects",[84],"2023-04-04","2023-01-31",96,[15],[2265,2280,2281,2282,2283,2284],"ARM B","ARM C","ARM D","ARM E","ARM F",{"trials":2286,"activeCount":12},[],{"trials":2288,"activeCount":12},[],{"trials":2290,"activeCount":12},[],{"trials":2292,"activeCount":12},[],{"intervention":2280,"totalTrials":357,"cells":2294},{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2303,"PHASE3":2305,"PHASE4":2307,"NA":2309},{"trials":2296,"activeCount":12},[],{"trials":2298,"activeCount":12},[2299],{"nctId":2272,"briefTitle":2273,"status":100,"phases":2300,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":2277,"conditions":2301,"interventions":2302},[84],[15],[2265,2280,2281,2282,2283,2284],{"trials":2304,"activeCount":12},[],{"trials":2306,"activeCount":12},[],{"trials":2308,"activeCount":12},[],{"trials":2310,"activeCount":12},[],{"intervention":2281,"totalTrials":357,"cells":2312},{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2321,"PHASE3":2323,"PHASE4":2325,"NA":2327},{"trials":2314,"activeCount":12},[],{"trials":2316,"activeCount":12},[2317],{"nctId":2272,"briefTitle":2273,"status":100,"phases":2318,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":2277,"conditions":2319,"interventions":2320},[84],[15],[2265,2280,2281,2282,2283,2284],{"trials":2322,"activeCount":12},[],{"trials":2324,"activeCount":12},[],{"trials":2326,"activeCount":12},[],{"trials":2328,"activeCount":12},[],{"intervention":2282,"totalTrials":357,"cells":2330},{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2339,"PHASE3":2341,"PHASE4":2343,"NA":2345},{"trials":2332,"activeCount":12},[],{"trials":2334,"activeCount":12},[2335],{"nctId":2272,"briefTitle":2273,"status":100,"phases":2336,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":2277,"conditions":2337,"interventions":2338},[84],[15],[2265,2280,2281,2282,2283,2284],{"trials":2340,"activeCount":12},[],{"trials":2342,"activeCount":12},[],{"trials":2344,"activeCount":12},[],{"trials":2346,"activeCount":12},[],{"intervention":2283,"totalTrials":357,"cells":2348},{"EARLY_PHASE1":2349,"PHASE1":2351,"PHASE2":2357,"PHASE3":2359,"PHASE4":2361,"NA":2363},{"trials":2350,"activeCount":12},[],{"trials":2352,"activeCount":12},[2353],{"nctId":2272,"briefTitle":2273,"status":100,"phases":2354,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":2277,"conditions":2355,"interventions":2356},[84],[15],[2265,2280,2281,2282,2283,2284],{"trials":2358,"activeCount":12},[],{"trials":2360,"activeCount":12},[],{"trials":2362,"activeCount":12},[],{"trials":2364,"activeCount":12},[],{"intervention":2284,"totalTrials":357,"cells":2366},{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2381},{"trials":2368,"activeCount":12},[],{"trials":2370,"activeCount":12},[2371],{"nctId":2272,"briefTitle":2273,"status":100,"phases":2372,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":2277,"conditions":2373,"interventions":2374},[84],[15],[2265,2280,2281,2282,2283,2284],{"trials":2376,"activeCount":12},[],{"trials":2378,"activeCount":12},[],{"trials":2380,"activeCount":12},[],{"trials":2382,"activeCount":12},[],{"intervention":2384,"totalTrials":357,"cells":2385},"HRS-1780 table or placebo",{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2397,"PHASE3":2399,"PHASE4":2401,"NA":2403},{"trials":2387,"activeCount":12},[],{"trials":2389,"activeCount":12},[2390],{"nctId":2391,"briefTitle":2392,"status":142,"phases":2393,"primaryCompletion":1116,"completion":1116,"start":2394,"enrollment":2277,"conditions":2395,"interventions":2396},"NCT05638126","Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects",[84],"2023-02-02",[24],[2384,2384,2384],{"trials":2398,"activeCount":12},[],{"trials":2400,"activeCount":12},[],{"trials":2402,"activeCount":12},[],{"trials":2404,"activeCount":12},[],{"intervention":2406,"totalTrials":357,"cells":2407},"[14C]HRS-7535",{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2421,"PHASE3":2423,"PHASE4":2425,"NA":2427},{"trials":2409,"activeCount":12},[],{"trials":2411,"activeCount":12},[2412],{"nctId":2413,"briefTitle":2414,"status":100,"phases":2415,"primaryCompletion":2416,"completion":2416,"start":2417,"enrollment":19,"conditions":2418,"interventions":2420},"NCT06819488","A Clinical Study of Mass Balance of [14C]HRS-7535",[84],"2025-04-16","2025-02-27",[21,2419],"Weight Loss",[2406],{"trials":2422,"activeCount":12},[],{"trials":2424,"activeCount":12},[],{"trials":2426,"activeCount":12},[],{"trials":2428,"activeCount":12},[],{"intervention":2430,"totalTrials":357,"cells":2431},"FDC",{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2446,"PHASE3":2448,"PHASE4":2450,"NA":2452},{"trials":2433,"activeCount":12},[],{"trials":2435,"activeCount":12},[2436],{"nctId":2437,"briefTitle":2438,"status":142,"phases":2439,"primaryCompletion":2440,"completion":2441,"start":2442,"enrollment":2063,"conditions":2443,"interventions":2445},"NCT05120219","A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers",[84],"2021-11-17","2021-12-20","2021-10-13",[2444],"Type II Diabetes",[2430,2430,2430],{"trials":2447,"activeCount":12},[],{"trials":2449,"activeCount":12},[],{"trials":2451,"activeCount":12},[],{"trials":2453,"activeCount":12},[],{"intervention":2455,"totalTrials":357,"cells":2456},"HR20031 FDC",{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2468,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2458,"activeCount":12},[],{"trials":2460,"activeCount":12},[2461],{"nctId":2462,"briefTitle":2463,"status":100,"phases":2464,"primaryCompletion":2465,"completion":2465,"start":2276,"enrollment":157,"conditions":2466,"interventions":2467},"NCT05692934","A HR20031 FE Study on Healthy Subjects",[84],"2023-03-11",[15],[2455,2455,2455,2455],{"trials":2469,"activeCount":12},[],{"trials":2471,"activeCount":12},[],{"trials":2473,"activeCount":12},[],{"trials":2475,"activeCount":12},[],{"intervention":2477,"totalTrials":357,"cells":2478},"T1: FDC 5\u002F500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR",{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2494,"PHASE3":2496,"PHASE4":2498,"NA":2500},{"trials":2480,"activeCount":12},[],{"trials":2482,"activeCount":12},[2483],{"nctId":2484,"briefTitle":2485,"status":142,"phases":2486,"primaryCompletion":2487,"completion":2488,"start":2489,"enrollment":2490,"conditions":2491,"interventions":2492},"NCT05108350","A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects",[84],"2021-12-03","2021-12-10","2021-11-09",80,[2444],[2477,2477,2493,2493],"T2: FDC 5\u002F1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR",{"trials":2495,"activeCount":12},[],{"trials":2497,"activeCount":12},[],{"trials":2499,"activeCount":12},[],{"trials":2501,"activeCount":12},[],{"intervention":2493,"totalTrials":357,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2512,"PHASE3":2514,"PHASE4":2516,"NA":2518},{"trials":2505,"activeCount":12},[],{"trials":2507,"activeCount":12},[2508],{"nctId":2484,"briefTitle":2485,"status":142,"phases":2509,"primaryCompletion":2487,"completion":2488,"start":2489,"enrollment":2490,"conditions":2510,"interventions":2511},[84],[2444],[2477,2477,2493,2493],{"trials":2513,"activeCount":12},[],{"trials":2515,"activeCount":12},[],{"trials":2517,"activeCount":12},[],{"trials":2519,"activeCount":12},[],{"intervention":162,"totalTrials":357,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2530,"PHASE3":2532,"PHASE4":2534,"NA":2536},{"trials":2523,"activeCount":12},[],{"trials":2525,"activeCount":12},[2526],{"nctId":152,"briefTitle":153,"status":100,"phases":2527,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":2528,"interventions":2529},[84],[159,160],[45,162,163,164,165],{"trials":2531,"activeCount":12},[],{"trials":2533,"activeCount":12},[],{"trials":2535,"activeCount":12},[],{"trials":2537,"activeCount":12},[],{"intervention":163,"totalTrials":357,"cells":2539},{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2548,"PHASE3":2550,"PHASE4":2552,"NA":2554},{"trials":2541,"activeCount":12},[],{"trials":2543,"activeCount":12},[2544],{"nctId":152,"briefTitle":153,"status":100,"phases":2545,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":2546,"interventions":2547},[84],[159,160],[45,162,163,164,165],{"trials":2549,"activeCount":12},[],{"trials":2551,"activeCount":12},[],{"trials":2553,"activeCount":12},[],{"trials":2555,"activeCount":12},[],{"intervention":165,"totalTrials":357,"cells":2557},{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2566,"PHASE3":2568,"PHASE4":2570,"NA":2572},{"trials":2559,"activeCount":12},[],{"trials":2561,"activeCount":12},[2562],{"nctId":152,"briefTitle":153,"status":100,"phases":2563,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":2564,"interventions":2565},[84],[159,160],[45,162,163,164,165],{"trials":2567,"activeCount":12},[],{"trials":2569,"activeCount":12},[],{"trials":2571,"activeCount":12},[],{"trials":2573,"activeCount":12},[]]